Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

BGLC BioNexus Gene Lab Corp Common stock
$0.82 -0.12% 0.00
Notify me if price changes either direction
Interactive Brokers Logotype

Buy BGLC stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades

BioNexus Gene Lab Corp Common stock (BGLC)

Loading

Key Stats

Market cap. 2.4M
Enterprise value -789979
Trailing PE -0.51026757488951
PEG Ratio 0.0077787456972045
Enterprise to EBITDA 0.299
Enterprise to revenue -0.253
Price to book MRQ 0.2551274
Price to sales TTM 0.7702839

Financials

Fiscal Year Ends 2025-12-31
Most Recent Quarter (MRQ) 2026-06-30
Revenue (TTM) 3.1M
EBITDA -2640000
Diluted EPS TTM -1.26
Total Cash (MRQ) 3.5M
Current ratio (MRQ) 6.081
Operating Cash Flow (TTM) -846565

BGLC trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent BGLC News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.